Excalibur Group Holdings

Takeda Cambridge Limited (TCB) and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology and metabolic-related diseases.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Intercytex Group is a biotechnology company focused on the research, development, and commercialization of cell-based therapies aimed at repairing and regenerating skin and hair. The company utilizes an integrated cell technology platform to create living, human cell-based products. Its key development programs include VAVELTA, designed for facial rejuvenation and skin damage repair, which has completed Phase II trials; SHEF-1-Stem Cell Line, intended to address age-related macular degeneration, a leading cause of blindness; ICX-TRC, a hair regeneration product that has also completed Phase II trials; and ICX-SKN, a skin graft replacement for burns and acute wounds, which has completed Phase I trials. Additionally, Intercytex is developing ICX-RHY, targeting skin-related issues such as epidermolysis bullosa and scar contractures. Founded in 2000, the company is headquartered in Cambridge, United Kingdom.

Takeda Cambridge Limited (TCB) and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology and metabolic-related diseases.

Plethora Solutions is a specialty pharmaceutical company focused on developing and marketing products for the treatment and management of urological disorders. The company addresses a growing market characterized by many unmet medical needs, presenting significant opportunities for innovation in pharmaceutical products and medical devices. Its principal product is a treatment for male premature ejaculation, which received marketing authorization from the European Commission in November 2013. Plethora Solutions is committed to improving the quality of life for patients suffering from urological conditions through its dedicated efforts in drug development and marketing.

DestinationSkin operates non-surgical beauty clinics in London and Swindon, United Kingdom, specializing in laser hair removal and advanced skin treatments. The company provides a range of cosmetic services tailored to meet the individual needs of its patients. Each client receives a personalized consultation to address specific skin concerns and aging issues, ensuring that the recommended treatments are bespoke. DestinationSkin aims to deliver high-quality care in a professional environment, focusing on customer satisfaction and effective results.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders. The company focuses on the discovery and development of inhibitors to find clinical utility in various diseases, including cancer, immune inflammatory disorders, cardiovascular disease, and pain, as well as metabolic and infectious diseases. The company was incorporated in 2001 and is based in Slough, the United Kingdom. As of May 23, 2008, Piramed Limited operates as a subsidiary of Hoffmann-La Roche Inc.

Energist Ltd specializes in the design, manufacture, marketing, and supply of lasers and light-based systems for hair removal and aesthetic skin treatments within the medical and beauty sectors. The company offers a range of products, including variable and intense pulsed light systems for hair removal and skin rejuvenation, as well as laser systems such as light emitting diode (LED) and CO2 lasers for medical and surgical applications. Additionally, Energist provides LED systems and micro-needle rollers aimed at anti-aging treatments. Its products cater to various aesthetic and surgical needs, including vascular treatments, skin rejuvenation, resurfacing, and regeneration. Energist sells its products both directly and through a network of distributors globally. Founded in 1999, the company is headquartered in Swansea, United Kingdom, and operates as a subsidiary of Energist Medical Group.

Arakis Limited is engaged in the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The company specializes in understanding cytokine and receptor-mediated mechanisms of disease, which informs its research and development efforts. Arakis identifies and commercializes product opportunities by exploring new clinical applications for established drugs and drug templates, as well as enhancing the performance of existing medicines. Through its innovative approach, Arakis aims to address unmet medical needs in the therapeutic areas of inflammatory disease and pain.

Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

EpiCept Corporation headquarters are located in Englewood Cliffs, New Jersey, with a subsidiary company, EpiCept GmbH in Munich Germany. This transatlantic presence facilitates access to European technology and markets and enhances financing and liquidity opportunities. EpiCept and its subsidiary are focused on developing novel, effective, safe and economical prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes. It is envisioned that EpiCept products will have significant market potential. The products are protected by an aggressive patent program.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.

Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

Arakis Limited is engaged in the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The company specializes in understanding cytokine and receptor-mediated mechanisms of disease, which informs its research and development efforts. Arakis identifies and commercializes product opportunities by exploring new clinical applications for established drugs and drug templates, as well as enhancing the performance of existing medicines. Through its innovative approach, Arakis aims to address unmet medical needs in the therapeutic areas of inflammatory disease and pain.

Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Vectura Group is a specialist company focused on the development of pharmaceutical therapies for airways-related diseases, primarily targeting asthma and chronic obstructive pulmonary disease (COPD). With a significant market estimated to exceed $30 billion globally, Vectura offers an integrated inhaled drug delivery platform, which includes inhaled product formulation and device design. The company aims to improve treatment options for patients suffering from these conditions by leveraging its expertise in inhaled drug delivery technologies.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for cancer and other proliferative diseases. Founded in 1996 by Professor Sir David Lane, a pioneer in tumor suppressor biology, the company specializes in targeting cell cycle control mechanisms. Its oncology programs include CYC065, a cyclin-dependent kinase inhibitor currently in Phase I trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase inhibitor also in Phase I trials for advanced leukemias. Additionally, Cyclacel is advancing sapacitabine, an oral nucleoside analogue, through multiple studies, including a Phase III trial for acute myeloid leukemia and combination studies with other agents for patients with BRCA mutations. The company collaborates with the University of Texas MD Anderson Cancer Center to evaluate the safety and efficacy of its drugs in hematological malignancies, and has a partnership with ManRos Therapeutics for the development of oral seliciclib capsules for cystic fibrosis. Cyclacel is headquartered in Berkeley Heights, New Jersey.

ReNeuron Group is a biotechnology company based in the United Kingdom, focused on the research and development of cell-based therapies for various medical conditions. Established in 1997, the company is advancing its CTX stem cell therapy candidate, which is currently undergoing Phase IIb clinical trials aimed at addressing stroke disability. Additionally, ReNeuron is developing human retinal progenitor cell therapy, which is in Phase I/IIa trials for the treatment of retinitis pigmentosa, a genetic disorder leading to blindness. The company's product pipeline also includes therapies for other neurodegenerative diseases, such as Parkinson's disease and Type 1 diabetes. ReNeuron is exploring CTX-derived exosomes, which are nanoscale entities that facilitate cellular communication. Furthermore, the company has established research collaborations to develop innovative gene silencing-based therapeutics, underlining its commitment to advancing stem cell technologies for both therapeutic and non-therapeutic applications.